Seattle Times Article last night listed about 10 Biotechs showing how much cash each one had and the importance of this cash in keeping them afloat. BTGC wasn't listed of course as it's never on the biotech screen. I wonder how much cash it has left?
After paying down the debt, it has about 100 Million. BTG doesn't need the cash to survive. It is profitable. The cash will be used to buy another company. This is what they have stated over the past year. They are looking for acquisitions.
They bought Meylos last year with cash and stock last year.